FY2017 Earnings Estimate for Pacific Biosciences of California, Inc. Issued By William Blair (PACB)

Pacific Biosciences of California, Inc. (NASDAQ:PACB) – Investment analysts at William Blair upped their FY2017 earnings per share estimates for shares of Pacific Biosciences of California in a research report issued to clients and investors on Tuesday. William Blair analyst A. Murphy now forecasts that the biotechnology company will post earnings of ($0.89) per share for the year, up from their prior forecast of ($0.95). William Blair also issued estimates for Pacific Biosciences of California’s Q4 2017 earnings at ($0.19) EPS, Q1 2018 earnings at ($0.16) EPS, Q2 2018 earnings at ($0.16) EPS, Q3 2018 earnings at ($0.14) EPS, Q4 2018 earnings at ($0.14) EPS, FY2018 earnings at ($0.60) EPS and FY2019 earnings at ($0.42) EPS.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.19) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.01. The firm had revenue of $23.54 million during the quarter, compared to analyst estimates of $28.29 million. Pacific Biosciences of California had a negative return on equity of 97.50% and a negative net margin of 95.97%. The business’s quarterly revenue was down 6.3% compared to the same quarter last year. During the same period last year, the company posted ($0.19) EPS.

COPYRIGHT VIOLATION NOTICE: “FY2017 Earnings Estimate for Pacific Biosciences of California, Inc. Issued By William Blair (PACB)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/11/fy2017-earnings-estimate-for-pacific-biosciences-of-california-inc-issued-by-william-blair-pacb.html.

Several other equities research analysts have also issued reports on the company. CL King lowered Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $6.80 price target for the company. in a report on Thursday, September 28th. BidaskClub lowered Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a report on Thursday, July 27th. First Analysis lowered Pacific Biosciences of California from an “overweight” rating to an “equal weight” rating and set a $4.00 price target for the company. in a report on Friday, November 3rd. Finally, Zacks Investment Research lowered Pacific Biosciences of California from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $6.27.

Shares of Pacific Biosciences of California (NASDAQ:PACB) opened at $2.92 on Friday. The company has a current ratio of 3.75, a quick ratio of 3.15 and a debt-to-equity ratio of 0.10. Pacific Biosciences of California has a 1-year low of $2.66 and a 1-year high of $8.32.

Several institutional investors have recently made changes to their positions in PACB. HighTower Advisors LLC lifted its holdings in shares of Pacific Biosciences of California by 35.1% during the 2nd quarter. HighTower Advisors LLC now owns 27,785 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 7,225 shares during the last quarter. Karp Capital Management Corp acquired a new stake in shares of Pacific Biosciences of California during the 1st quarter valued at about $116,000. Voya Investment Management LLC lifted its holdings in shares of Pacific Biosciences of California by 17.5% during the 2nd quarter. Voya Investment Management LLC now owns 41,653 shares of the biotechnology company’s stock valued at $148,000 after buying an additional 6,218 shares during the last quarter. BlueCrest Capital Management Ltd acquired a new stake in shares of Pacific Biosciences of California during the 2nd quarter valued at about $155,000. Finally, Aperio Group LLC raised its stake in shares of Pacific Biosciences of California by 105.5% in the 3rd quarter. Aperio Group LLC now owns 42,396 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 21,766 shares in the last quarter. Institutional investors and hedge funds own 68.09% of the company’s stock.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Earnings History and Estimates for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply